FCM
SUPN icon

Fieldview Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Fieldview Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,600
Closed -$238K – 700
2026
Q1 		$238K Sell
4,600
-274
-6% -$14K 0.07% 410
2025
Q4 		$242K Buy
+4,874
New +$237K 0.04% 422

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Fieldview Capital Management's SUPN Position: Q2 2026 in Review

Fieldview Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 4,600 shares — an estimated $238K sold.

Fieldview Capital Management first reported a position in SUPN in Q4 2025 and held it in 2 quarters. The position peaked at $242K in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Fieldview Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 4,600 Supernus Pharmaceuticals shares in Q2 2026, an estimated $238K.
  • Fieldview Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Fieldview Capital Management's Supernus Pharmaceuticals position peaked at $242K in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.